Is the business good?
How good a business is ZTS?
Zoetis keeps 27% of every revenue dollar as profit after everything, against 6.3% for the median Drug Manufacturers - Specialty & Generic name.
27%
Net margin · Drug Manufacturers - Specialty & Generic median 6.3% · 12 months to Q2 2026
- Cash conversion
- 0.89×
Cash conversion · 0.88× a year ago · some of the reported profit has not turned into cash yet
- Share count, year on year
- −6.2%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 7.6%
R&D as % of revenue
Details›
- Gross margin12 months to Q2 2026
- 72%
- Net margin12 months to Q2 2026
- 27%
- Free cash flow margin
- 24%
- R&D as % of revenue
- 7.6%
- Revenue, trailing twelve months
- $9.52B
- Free cash flow, trailing twelve months
- $2.32B
- Net income, trailing twelve months
- $2.62B
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #5 of 28 by Smart Score